- Trials with a EudraCT protocol (196)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
196 result(s) found for: Emotional safety.
Displaying page 1 of 10.
EudraCT Number: 2021-003514-39 | Sponsor Protocol Number: GNCbumet | Start Date*: Information not available in EudraCT |
Sponsor Name:Gillberg Neuropsychiatry Centre | ||
Full Title: Testing E/I imbalance in autism with Bumetanide – a parallel group randomized waitlist-control trial in adolescents and adults | ||
Medical condition: Autism Spectrum Disorder | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000749-21 | Sponsor Protocol Number: 4.20 | Start Date*: 2016-03-14 |
Sponsor Name:Medizinische Hochschule Hannover | ||
Full Title: Botulinumtoxin A for emotional stabilization in borderline personality disorder | ||
Medical condition: Borderline personality disorder | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000712-30 | Sponsor Protocol Number: ABR-71432 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation | |||||||||||||
Medical condition: Posttraumatic Stress Disorder (PTSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004823-66 | Sponsor Protocol Number: ELTCAN1 | Start Date*: 2019-04-17 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Early-life stress, the endocannabinoid system, and fear memory extinction | |||||||||||||
Medical condition: healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004548-31 | Sponsor Protocol Number: HUB-PSI-CAMAD | Start Date*: 2020-04-18 | ||||||||||||||||
Sponsor Name:Cinto Segalàs | ||||||||||||||||||
Full Title: A RANDOMIZED, CONTROLLED, OPEN AND UNICENTRIC PHASE II CLINICAL TRIAL, WITH TWO PARALLEL GROUPS, TO EVALUATE THE ANTIDEPRESSANT EFFICACY OF PSYCHOTHERAPY AND CITALOPRAM IN WOMEN DIAGNOSED WITH BREA... | ||||||||||||||||||
Medical condition: Female patients diagnosed with breast cancer who, during the first year following the diagnosis of oncological disease, have affective symptomatology that meets DSM-V criteria for major depression. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004829-33 | Sponsor Protocol Number: 17797A | Start Date*: 2018-10-03 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: Interventional, open-label, flexible-dose study of vortioxetine on emotional functioning in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment | |||||||||||||
Medical condition: Emotional functioning in patients with MDD | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) LT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000377-68 | Sponsor Protocol Number: CT-4006 | Start Date*: 2018-07-03 | |||||||||||
Sponsor Name:SynCore Biotechnology Co., Ltd. | |||||||||||||
Full Title: A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/o... | |||||||||||||
Medical condition: Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005320-17 | Sponsor Protocol Number: CL3-20098-060 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre stu... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001234-32 | Sponsor Protocol Number: TOPMAT-MIG-3006 | Start Date*: 2005-08-22 |
Sponsor Name:Janssen Cilag International NV | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age. Estudio aleatoriz... | ||
Medical condition: Migraine in Pediatric Population (12-17 year olds, inclusive) | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) FI (Completed) NO (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003983-30 | Sponsor Protocol Number: CPH-303-201400 | Start Date*: 2019-05-22 | |||||||||||
Sponsor Name:Croma-Pharma GmbH | |||||||||||||
Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study. | |||||||||||||
Medical condition: Moderate to severe glabellar lines | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006561-32 | Sponsor Protocol Number: OxyCog-01 | Start Date*: 2009-11-05 |
Sponsor Name:LWL University Hospital Bochum | ||
Full Title: Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disorders | ||
Medical condition: Schizophrenia, bipolar disorder, major depression, personality disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004606-60 | Sponsor Protocol Number: BP42772 | Start Date*: 2021-06-22 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS W... | |||||||||||||
Medical condition: Advanced or metastatic squamous cell carcinoma of the esophagus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) BE (Prematurely Ended) FR (Trial now transitioned) IT (Trial now transitioned) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001383-28 | Sponsor Protocol Number: M18-891 | Start Date*: 2018-10-30 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis | |||||||||||||
Medical condition: Moderate and Severe Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) DK (Trial now transitioned) PT (Ongoing) CZ (Trial now transitioned) DE (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002164-16 | Sponsor Protocol Number: CPH-301-201030 | Start Date*: 2016-04-11 | |||||||||||
Sponsor Name:CROMA-PHARMA GmbH | |||||||||||||
Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study | |||||||||||||
Medical condition: Moderate to severe glabellar lines | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002089-11 | Sponsor Protocol Number: CMBG453B12301 | Start Date*: 2020-06-23 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodyspla... | ||||||||||||||||||
Medical condition: adult subjects with intermediate, high or very high risk (per IPSS-R prognostic risk categories) myelodysplastic syndrome or with Chronic Myelomonocytic Leukemia - 2 (CMML-2) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) IT (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) FI (Prematurely Ended) LT (Completed) NL (Prematurely Ended) GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004803-39 | Sponsor Protocol Number: SA-NXY-0007 | Start Date*: 2005-10-07 |
Sponsor Name:AstraZeneca AB | ||
Full Title: SAINT II (Stroke - Acute Ischemic - NXY Treatment) A double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous ... | ||
Medical condition: Acute ischemic stroke. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) HU (Completed) SK (Completed) ES (Completed) BE (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007580-24 | Sponsor Protocol Number: EB70 | Start Date*: 2008-02-08 |
Sponsor Name:Emotional Brain | ||
Full Title: A double blind, randomized, 3-arm placebo controlled study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female subj... | ||
Medical condition: Hypoactive sexual desire disorder and female sexual arousal disorder | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016790-15 | Sponsor Protocol Number: EB78 | Start Date*: 2009-12-03 |
Sponsor Name:Emotional Brain | ||
Full Title: A double blind, randomized, cross-over placebo controlled study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female... | ||
Medical condition: Hypoactive Sexual Desire Disorder (comorbidity with other sexual dysfunctions e.g Female Sexual Arousal Disorder (FSAD) is allowed) and/or SSRI induced sexual dysfunctioning. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002735-32 | Sponsor Protocol Number: EB72 | Start Date*: 2008-06-24 |
Sponsor Name:Emotional Brain | ||
Full Title: A double blind, randomized, placebo controlled cross-over study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female... | ||
Medical condition: Hypoactive sexual desire disorder and female sexual arousal disorder in combination with SSRI use. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-003889-42 | Sponsor Protocol Number: RN1001-319-1009 | Start Date*: 2008-08-26 | |||||||||||
Sponsor Name:Renovo | |||||||||||||
Full Title: A double blind, placebo controlled, randomised trial to investigate the efficacy of Juvista in the prevention or improvement of scar appearance when administered intradermally to approximated wound... | |||||||||||||
Medical condition: Patients undergoing scar revision surgery are left with scarring, which can vary from fine flat asymptomatic scars to hypertrophic scars. Studies show that these visible marks can cause emotional d... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
